- Home
- CLBT vs DNLI Comparison
CLBT vs DNLI Comparison
Compare CLBT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLBT | DNLI |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.2B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CLBT | DNLI |
|---|---|---|
| Price | $13.61 | $20.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $22.50 | ★ $31.20 |
| AVG Volume (30 Days) | ★ 2.2M | 1.5M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.45 | N/A |
| Revenue Next Year | $17.47 | $262.52 |
| P/E Ratio | $45.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.76 | $10.57 |
| 52 Week High | $20.86 | $23.77 |
Technical Indicators
Market Signals| Indicator | CLBT | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 55.29 |
| Support Level | $13.11 | $13.29 |
| Resistance Level | $15.13 | $23.77 |
| Average True Range (ATR) | 0.78 | 1.19 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 50.97 | 60.80 |
Price Performance
Historical ComparisonAbout CLBT Cellebrite DI Ltd.
Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze, and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.